Andrew Copestake Ph.D., FRSM

Chief Commercial Officer

As chief commercial officer, Dr. Andrew Copestake leads Caidya’s commercial strategy, sales, business development and customer success teams, creating accountability within the company as it continues to scale and achieve growth targets.

Andrew is an entrepreneurial, commercially focused, senior executive with almost 30 years of experience in the pharmaceutical, biotechnology and CRO industries. He has held positions across the sector at all levels from academic researcher to chief executive and has gained significant international experience from working in global positions and during assignments in the US, Japan and throughout Europe. Andrew has also held numerous board-level positions driving corporate strategy and fund-raising and has become an expert in business development, general management, partnering (in-/out-licensing) and product development with a successful track record of delivering sales, growth and enhancing profitability. He is a strong, decisive leader with an ability to manage businesses through significant change while delivering key performance indicators.

Andrew holds a PhD in Respiratory & Exercise Physiology from Loughborough University, UK and a BA Hons in Applied Biology from East London University, UK. He is also a Fellow of the Royal Society of Medicine.

Leading a new way

The latest from Caidya

Explore our news and updates as we liberate the clinical research process.

06/12/2024

Caidya Achieves Medidata Rave TSDV Accreditation, Enhancing Clinical Trial Efficiency and Data Integrity

Raleigh, N.C., June 12, 2024 – Caidya, a leading provider...

04/01/2024

Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto

Morrisville, NC, USA, April 1, 2024 - Caidya, a leading...

Gene Therapy Development 2024

13th June 2024 to 14th June 2024
London, UK
Skip to toolbar